

## Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

*Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment<sup>1</sup> that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.*

**Leuven, BELGIUM – 10 October, 2024 – 06:00 PM CET** – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, [Oxurion NV](#) (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 452,841 new ordinary shares on October 8, 2024, for a total amount of EUR 150,000 pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.

Following completion of capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,002,550 outstanding ordinary shares carrying voting rights (compared to 1,549,709 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

- |  |               |
|--|---------------|
| • Share capital (EUR)  | 85,006,161.32 |
| • Total number of securities with voting rights (all ordinary shares)  | 2,002,550     |
| • Total number of ordinary shares (= denominator)  | 2,002,550     |
| • Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued (excluding any shares resulting (a) from the potential conversion of any convertibles bonds issued on December 20, 2021 to the benefit of Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P. or (b) from the exercise of any subscription rights issued by the Company to the benefits of employees, consultants or directors of the Company (as they are both currently significantly out-of-the-money):   |               |
| ▪ 354 convertible bonds issued on March 14, 2023, April 20, 2023, May 22, 2023, June 15, 2023, August 10, 2023, September 15, 2023, October 20, 2023, October 24, 2023, November 15, 2023 and November 15, 2023, January 9, 2024, February 2, 2024, March 4, 2024, April 10, 2024, May 22, 2024, June 5, 2024, July 12, 2024, August 20, 2024, September 3, 2024 and October 8, entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into |               |

<sup>1</sup> [Press release Oxurion, 02/03/2023](#)

between the Company and Atlas Special Opportunities, LLC on March 1, 2023, as amended on September 10, 2023 and December 22, 2023.

END

### About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at [www.oxurion.com](http://www.oxurion.com).

### **Important information about forward-looking statements**

*Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.*

### **Please contact for additional information:**

<p>Oxurion NV Pascal Ghoson Chief Executive Officer <a href="mailto:pascal.ghoson@oxurion.com">pascal.ghoson@oxurion.com</a></p>
--